GZMB and neoplasm: Breunig et al. [98] demonstrated that miR-519a-3p can efficiently impair tumor cell killing by NKs and confer BCCs resistance by targeting TRAIL, FasL and granzyme B. The authors further showed that this is achieved via the downregulation of UL16-binding protein 2 (ULBP2) and major histocompatibility complex class I chain-related protein A (MICA) in the surface of tumor cells.